IMGS-203 / ImmunoGenesis - LARVOL DELTA

First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models (ASH 2025) - "Additionally,77A markedly enhanced anti-tumor activity of proteosome inhibitors (bortezomib and carfilzomib),radiation, and STING agonists (diABZI and IACS-8803) in MPC11 and Vk*MYC models. 77A is a first-in-class anti-HSP70 antibody that uniquely leverages HSP70 neoantigen biology to bridgeinnate and adaptive immunity. It generates robust and durable anti-tumor activity in hematologic andsolid tumor models, and synergizes with multiple immunomodulatory and standard therapies,supporting its clinical translation as a novel immunotherapy platform."

Immunomodulating • IO biomarker • Preclinical • Breast Cancer • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • CD4 • CD8

Intratumoral STING activation with IMGS-203 drives anti-tumor responses in glioblastoma: Preclinical efficacy, safety, and pharmacokinetic profile (SITC 2025) - "Safety studies showed that mice tolerated high dose intracranial IMGS-203, while dogs were more susceptible to local effects such as cerebral edema.Conclusions These data, together with previously published studies on potency, efficacy, and mechanism of action,1–4 will support the submission of an investigational new drug application for IMGS-203 as a treatment for GBM. The advantage of using IMGS-203 to treat GBM is that it does not need to be delivered to every cell to be effective, but by impacting the tumor microenvironment, it triggers innate and adaptive immune activation, leading to a potent antitumor effect."

PK/PD data • Preclinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • STING

A potent STING agonist induces endothelial PD-L1 and enhances antitumor efficacy of a novel PD-L1/PD-L2 antibody (AACR 2025) - "We previously demonstrated that combining a potent STING agonist (8803, IMGS-203) with a novel dual-specific anti-PD-L1/PD-L2 monoclonal antibody (27907) produced curative responses in checkpoint-refractory tumor models... Tumors treated with the combination of 8803 and 27907 exhibited extensive necrobiosis and endothelial damage, uniquely observed in the combination treatment group and correlating with curative outcomes. This enhanced antitumor response was associated with increased myeloid infiltration, a shift away from M2 macrophage phenotype, and an elevated effector T-cell population. These findings underscore the potent therapeutic synergy of 8803 with 27907 and support their further development for clinical applications."

Clinical • IO biomarker • Breast Cancer • Melanoma • Oncology • Solid Tumor • MRC1 • PD-L2 • SELP • STING

Leveraging innate immune sensors to generate durable anti-glioma adaptive immune responses (SNO 2024) - "In the immune checkpoint resistant Qki-/- Pten-/- P53-/- (QPP) glioma model, intratumoral treatment with the synthetic cyclic di-nucleotide STING agonist IACS-8803 (8803) induces global immunological reprogramming and long-term survival resistant to tumor rechallenge...Finally, the combination of 8803 and anti-CD47 synergizes to extend both median survival and the fraction of long-term survivors in orthotopic QPP-bearing mice (QPP8v; vehicle control MS=39d, anti-CD47 MS=40d, 8803 MS=67d 20% long-term survival, 8803 + anti-CD47 MS=107.5d 40% long-term survival). These data demonstrate that 8803 induces proinflammatory conversion of the glioblastoma TME, generates T cell-dependent survival benefits in QPP-bearing mice, and synergizes with anti-CD47 blockade to enhance microglia phagocytosis of glioblastoma cells and extend survival in QPP-bearing mice."

Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • CD163 • CD8 • CD86 • MRC1 • PTEN • SIRPA